Retracted: Role of hypoxia‐inducible factors in the dexrazoxane‐mediated protection of cardiomyocytes from doxorubicin‐induced toxicity
Open Access
- 14 January 2011
- journal article
- retracted article
- Published by Wiley in British Journal of Pharmacology
- Vol. 163 (2) , 299-312
Abstract
BACKGROUND AND PURPOSE: Iron aggravates the cardiotoxicity of doxorubicin, a widely used anticancer anthracycline, and the iron chelator dexrazoxane is the only agent protecting against doxorubicin cardiotoxicity; however, the mechanisms underlying the role of iron in doxorubicin‐mediated cardiotoxicity and the protective role of dexrazoxane remain to be established. As iron is required for the degradation of hypoxia‐inducible factors (HIF), which control the expression of antiapoptotic and protective genes, we tested the hypothesis that dexrazoxane‐dependent HIF activation may mediate the cardioprotective effect of dexrazoxane.EXPERIMENTAL APPROACH: Cell death, protein levels (by immunoblotting) and HIF‐mediated transcription (using reporter constructs) were evaluated in the rat H9c2 cardiomyocyte cell line exposed to low doses of doxorubicin with or without dexrazoxane pretreatment. HIF levels were genetically manipulated by transfecting dominant‐negative mutants or short hairpin RNA.KEY RESULTS: Treatment with dexrazoxane induced HIF‐1α and HIF‐2α protein levels and transactivation capacity in H9c2 cells. It also prevented the induction of cell death and apoptosis by exposure of H9c2 cells to clinically relevant concentrations of doxorubicin. Suppression of HIF activity strongly reduced the protective effect of dexrazoxane. Conversely, HIF‐1α overexpression protected against doxorubicin‐mediated cell death and apoptosis also in cells not exposed to the chelator. Exposure to dexrazoxane increased the expression of the HIF‐regulated, antiapoptotic proteins survivin, Mcl1 and haem oxygenase.CONCLUSIONS AND IMPLICATIONS: Our results showing HIF‐dependent prevention of doxorubicin toxicity in dexrazoxane‐treated H9c2 cardiomyocytes suggest that HIF activation may be a mechanism contributing to the protective effect of dexrazoxane against anthracycline cardiotoxicity.Keywords
This publication has 77 references indexed in Scilit:
- Transcription Factor GATA4 Inhibits Doxorubicin-induced Autophagy and Cardiomyocyte DeathJournal of Biological Chemistry, 2010
- Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell deathBritish Journal of Cancer, 2009
- RETRACTED: Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cellsProceedings of the National Academy of Sciences, 2009
- Differences in doxorubicin-induced apoptotic signaling in adult and immature cardiomyocytesFree Radical Biology and Medicine, 2008
- Role of HIF-1 and NF-κB Transcription Factors in the Modulation of Transferrin Receptor by Inflammatory and Anti-inflammatory SignalsJournal of Biological Chemistry, 2008
- Oxygen Sensing by Metazoans: The Central Role of the HIF Hydroxylase PathwayMolecular Cell, 2008
- Pharmacological Inhibition of CB1Cannabinoid Receptor Protects Against Doxorubicin-Induced CardiotoxicityJACC, 2007
- Protecting against anthracycline‐induced myocardial damage: a review of the most promising strategiesBritish Journal of Haematology, 2005
- Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and CardiotoxicityPharmacological Reviews, 2004
- A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicinBiochemical Pharmacology, 1999